Company intelligence / Profile preview
ViroMissile
La Jolla, California, United Statesviromissile.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ViroMissile is developing a “one-shot” cure for deadly cancers using its proprietary IDOV™ oncolytic virus platform. The company has four patent-pending drug candidates with unique functions, all in preparation for IND filing. Preclinical animal models show prolonged survival of the drugs in blood and tumors, enabling single-dose tumor destruction and robust anti-tumor immune responses. No clinical toxicity failures have been reported to date
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic viruses
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on ViroMissile.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ViroMissile.